Stanislaw R. Burzynski1*, Tomasz J. Janicki1, Gregory S. Burzynski1, Samuel W. Beenken2 and Radoslaw J. Siwiec3
Diffuse Intrinsic Pontine Glioma (DIPG) has one of the worst prognoses in neuro-oncology with median overall survival of approximately 11 months. The Adverse Events (AV) of standard therapy can be very serious. Twenty-eight patients with DIPG were treated with Antineoplastons A10 and AS2-1 (ANP) in Phase II clinical studies at Burzynski Clinic (BC). The unusually long-term survival and lack of chronic toxicity are discussed in this paper. Karnofsky/Lansky (KPS/LPS) performance score of thirty or higher and life expectancy of two months or more were required for admission for the treatment. ANP was administered intravenously via subclavian catheter and infusion pump. The goals of the study were determination of objective response, survival and toxicity. The median of the Kaplan-Meier survival analysis of 165 patients treated was 1.02 years (95% CI 0.93 ? 1.15). Twenty-eight patients (16.9%) survived from over three years to over 29 years. Eight patients from this group survived from over 12 years to over 29 years meeting criteria of cure. Age at admission of 28 long-term survivors was between 0.25 and 50 years. Three patients experienced possibly related Serious Adverse Events (SAE) including hypernatremia, vomiting and high fever without a bacterial infection, which were fully reversed. ANP shows promise in the treatment of DIPG.
Published Date: 2025-07-15; Received Date: 2025-06-17
